The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use. One of the most recent organizations to create utilization guidelines is the American Congress of Obstetricians and Gynecologists (ACOG), which released its guidelines in April 2015. Other guidelines are available from state medical boards, and the American Medical Association released a statement on the topic in 2010. The American Nurses Association (ANA) released a tool kit, which contain the ANA’s social networking principles, tips for nurses using social media, social media webinar, and a fact sheet.
ANA’s principles include not transmitting or posting identifiable patient information, observing patient-nurse boundaries, and being aware that colleagues and others have the ability to view what is posted. Nurses should utilize privacy settings and ideally, have separate personal and professional online accounts. Nurses also need to bring harmful content to the attention of appropriate individuals or authorities. The ANA notes that misuse of social media can not only damage the individual nurse’s reputation, but may damage the reputation of the nursing profession as well. The toolkit is available at http://www.nursingworld.org/socialnetworkingtoolkit.aspx.
Social Media: Risks and Benefits
The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use.
The use of social media is now so widespread that professional healthcare organizations have developed guidelines for its use. One of the most recent organizations to create utilization guidelines is the American Congress of Obstetricians and Gynecologists (ACOG), which released its guidelines in April 2015. Other guidelines are available from state medical boards, and the American Medical Association released a statement on the topic in 2010. The American Nurses Association (ANA) released a tool kit, which contain the ANA’s social networking principles, tips for nurses using social media, social media webinar, and a fact sheet.
ANA’s principles include not transmitting or posting identifiable patient information, observing patient-nurse boundaries, and being aware that colleagues and others have the ability to view what is posted. Nurses should utilize privacy settings and ideally, have separate personal and professional online accounts. Nurses also need to bring harmful content to the attention of appropriate individuals or authorities. The ANA notes that misuse of social media can not only damage the individual nurse’s reputation, but may damage the reputation of the nursing profession as well. The toolkit is available at http://www.nursingworld.org/socialnetworkingtoolkit.aspx.
Oncology Drugs Approved by the FDA in March 2025
The FDA approved treatments in various gastrointestinal and genitourinary cancers in March.
What New Cancer Drugs Were Approved in 2023?
In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
Relacorilant/Nab-Paclitaxel May Increase PFS, OS in Ovarian Cancer
Relacorilant in combination with nab-paclitaxel yielded higher PFS and OS in patients with platinum-resistant ovarian cancer vs nab-paclitaxel alone.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Elotuzumab/PVd Combo Elicits Response in Relapsed/Refractory MM
Elotuzumab plus pomalidomide, bortezomib, and dexamethasone showed tolerability in patients with relapsed or refractory multiple myeloma.
Camrelizumab Plus Rivoceranib Receives Second CRL in HCC
The complete response letter, issued by the FDA, does not identify what deficiencies regulators found in camrelizumab/rivoceranib for advanced HCC.
Oncology Drugs Approved by the FDA in March 2025
The FDA approved treatments in various gastrointestinal and genitourinary cancers in March.
What New Cancer Drugs Were Approved in 2023?
In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.
Relacorilant/Nab-Paclitaxel May Increase PFS, OS in Ovarian Cancer
Relacorilant in combination with nab-paclitaxel yielded higher PFS and OS in patients with platinum-resistant ovarian cancer vs nab-paclitaxel alone.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Elotuzumab/PVd Combo Elicits Response in Relapsed/Refractory MM
Elotuzumab plus pomalidomide, bortezomib, and dexamethasone showed tolerability in patients with relapsed or refractory multiple myeloma.
Camrelizumab Plus Rivoceranib Receives Second CRL in HCC
The complete response letter, issued by the FDA, does not identify what deficiencies regulators found in camrelizumab/rivoceranib for advanced HCC.
Latest Conference Coverage
Becoming Familiar With Patients’ AEs is Essential, Says Expert
Real-World Data Back First-Line Avelumab and Axitinib in Advanced RCC
Tivozanib Combo Yields Similar PROs to Monotherapy in Advanced Clear Cell RCC
Dose Reductions Possible for Tivozanib With and Without Nivolumab for RCC